We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Image: The acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data, and AI platform to advance cancer monitoring, deepen insights, and accelerate growth

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal

Tempus AI has entered into a definitive agreement to acquire Personalis, expanding its capabilities in MRD testing and cancer monitoring. More...
22 Jul 2026
Image: Despite treatment advances, most multiple myeloma patients relapse and identifying high-risk cases at diagnosis remains challenging (Image Credit: Adobe Stock)

New Marker Helps Detect Aggressive Multiple Myeloma Earlier

A new study links elevated cell-adhesion protein levels to shorter survival in newly diagnosed multiple myeloma. More...
22 Jul 2026
Multiplex immunofluorescent (left) and H&E-stained (right) breast tumor samples illustrating high versus low Base Topology Scores. Higher topology scores reflect more organized tissue architecture, while lower scores indicate greater structural disorganization. By quantitatively measuring these structural differences, the researchers developed biomarkers that predicted patient outcomes more accurately than many traditional approaches. (Photo courtesy of Columbia University Irving Medical Center)

Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response

A topology-based approach quantifies tumor architecture to improve breast cancer prognosis and predict therapy response. More...
22 Jul 2026
Image: A new study shows that an ultrasensitive blood test can detect immune signaling patterns associated with Sjögren’s disease more than a decade before diagnosis (Image Credit: 123RF)

Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis

A blood test detects early immune signatures up to a decade before Sjögren’s disease diagnosis. More...
21 Jul 2026
Image: The assay is designed to concurrently detect HSV-1, HSV-2, VZV, and MPXV in a single test (Image Credit: Adobe Stock)

Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions

Seegene USA’s Allplex HSV-1&2/VZV/MPXV Assay has received Emergency Use Authorization (EUA) from the U.S. FDA. More...
21 Jul 2026
Graphical Abstract: Changes in circulating tumor DNA during Ra-223 treatment reflect disease course in patients with bone-metastatic castration-resistant prostate cancer. (Image created by Masaki Shiota et al., Kyushu University, Fukuoka, Japan)

Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer

A new blood-based tumor DNA test predicts which patients benefit from radium-223 and tracks response to guide treatment in real time. More...
21 Jul 2026
Image: The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samples (Photo courtesy of Bruker)

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections

Bruker Corporationhas acquired the DISQVER clinical metagenomics platform, expanding its next-generation sequencing infection detection portfolio. More...
21 Jul 2026
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Automatic CLIA Analyzer
Shine i6000
Copyright © 2000-2026 Globetech Media. All rights reserved.